Condition: Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (Post-PV MF) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) · Sponsor: Novartis Pharmaceuticals
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +81337978748 · novartis.email@novartis.com
Novartis Pharmaceuticals · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Kamogawa, Chiba, Japan | Recruiting |
| Novartis Investigative Site | Sapporo, Hokkaido, Japan | Recruiting |
| Novartis Investigative Site | Kamakura, Kanagawa, Japan | Recruiting |
| Novartis Investigative Site | Kurashiki, Okayama-ken, Japan | Recruiting |
| Novartis Investigative Site | Bunkyo Ku, Tokyo, Japan | Recruiting |
| Novartis Investigative Site | Chūō, Yamanashi, Japan | Active Not Recruiting |
| Novartis Investigative Site | Kumamoto, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07340138